Health Insurance Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HepaLife Technologies
HepaLife enters into exclusive license agreement for flu vaccine development, including bird flu
August 13th, 2006
As part of its effort to expand its cell-based research and development activities, HepaLife Technologies, Inc., (HPLF), through a wholly owned subsidiary, announced that it has entered into an exclusive worldwide license agreement with Michigan State University (MSU) for the development of new cell-culture-based flu vaccines to protect against the spread of influenza viruses among humans, including potentially the high pathogenicity H5N1 virus. The license agreement gives HepaLife exclusive rights to five issued patents, including U.S. patent 5,989,805 ("Immortal Avian Cell Line To Grow Avian and Animal Viruses To Produce Vaccines"), U.S. patent 5,827,738, U.S. patent...
Source: Health Insurance Law Weekly (2006-08-13)
|
